Cary, N.C. , May 20, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by AbbVie as the exclusive specialty pharmacy provider for EMRELIS™ (telisotuzumab vedotin-tllv), an antibody-drug conjugate (ADC) for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE) who have received a prior systemic therapy. High c-Met protein overexpression is defined as ≥ 50% of tumor cells with strong (3+) staining as determined by an FDA-approved test.
EMRELIS™, approved by the U.S. Food and Drug Administration (FDA), is a first-in-class intravenous therapy targeting high c-Met protein overexpressing NSCLC. The c-Met protein is a receptor tyrosine kinase that is overexpressed in approximately 25% of advanced EGFR wild type, non-squamous NSCLC patients, and is often associated with a poor prognosis. Approximately half of these patients have high c-Met overexpression, defined as ≥ 50% of tumor cells with strong (3+) staining by immunohistochemistry (IHC) test.
NSCLC accounts for about 80-85% of lung cancer diagnoses, according to the American Cancer Society. While lung cancer is the leading cause of cancer-related deaths in the U.S., a decline in smoking and advancements in early detection and treatments is reducing this mortality rate.
Biologics by McKesson is committed to and recognized for its level of customer service as well as its innovative, high-touch, and multidisciplinary approach. Putting patients first in all they do, the Biologics’ pharmacy team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.
For the full prescribing information EMRELIS™, please click here. For more information about the treatment of NSCLC patients with c-Met protein overexpression, please click here.